TriangleNCT00550654 · STUDY IN CONTEXT
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Local control (e.g. absence of local progression) is defined as Complete response (CR), partial response (PR) or stable disease (SD) of the treated site(s). Complete response is the disappearance of the target lesion. Partial response is a \>/= 50% decrease in maximal dimension compared to pretreatment imaging. Stable disease does not qualify for CR, PR, or progression.Progression is an interval increase in the maximal dimension of the target lesion.
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
Interval from initiation of treatment on protocol to symptomatic or radiographic progression.
Local control (e.g. absence of local progression) is defined as Complete response (CR), partial response (PR) or stable disease (SD) of the treated site(s). Complete response is the disappearance of the target lesion. Partial response is a \>/= 50% decrease in maximal dimension compared to pretreatment imaging. Stable disease does not qualify for CR, PR, or progression. Progression is an interval increase in the maximal dimension of the target lesion.
Megavoltage localization scans will be obtained and the physician and therapist will evaluate the cone beam image and compare this image to the expected image based on the patient's initial planning CT scan.
Improvement in pain from baseline will be assessed by the Brief Inventory for Pain criteria.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- trial label
- Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 6
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0000
- source section id
- NCT00550654-om-0000
- source outcome index
- 0
- endpoint
- 6-month Local Control (i.e., Complete Response, Partial Response, or Stable Disease) at All Treated Sites of Metastatic Disease
- endpoint definition
- Local control (e.g. absence of local progression) is defined as Complete response (CR), partial response (PR) or stable disease (SD) of the treated site(s). Complete response is the disappearance of the target lesion. Partial response is a \>/= 50% decrease in maximal dimension compared to pretreatment imaging. Stable disease does not qualify for CR, PR, or progression.Progression is an interval increase in the maximal dimension of the target lesion.
- time origin
- 6 months
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- No data/specimens were collected. Study was terminated due to poor accrual.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0001
- source section id
- NCT00550654-om-0001
- source outcome index
- 1
- endpoint
- Number of Participants With Adverse Events
- endpoint definition
- Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
- time origin
- 9 months, 11 days
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0002
- source section id
- NCT00550654-om-0002
- source outcome index
- 2
- endpoint
- Median Time to Local Progression
- endpoint definition
- Interval from initiation of treatment on protocol to symptomatic or radiographic progression.
- time origin
- 6-12 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- No data/specimens were collected. Study was terminated due to poor accrual.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0003
- source section id
- NCT00550654-om-0003
- source outcome index
- 3
- endpoint
- 12 Month Local Control in All Sites of Treatment, and at Each Site of Treatment
- endpoint definition
- Local control (e.g. absence of local progression) is defined as Complete response (CR), partial response (PR) or stable disease (SD) of the treated site(s). Complete response is the disappearance of the target lesion. Partial response is a \>/= 50% decrease in maximal dimension compared to pretreatment imaging. Stable disease does not qualify for CR, PR, or progression. Progression is an interval increase in the maximal dimension of the target lesion.
- time origin
- 12 months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- No data/specimens were collected. Study was terminated due to poor accrual.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0004
- source section id
- NCT00550654-om-0004
- source outcome index
- 4
- endpoint
- Interfraction and Intrafraction Motion With Megavoltage Computed Tomography (CT) Based on Sites of Metastasis
- endpoint definition
- Megavoltage localization scans will be obtained and the physician and therapist will evaluate the cone beam image and compare this image to the expected image based on the patient's initial planning CT scan.
- time origin
- One to three months of followup
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- No data/specimens were collected. Study was terminated due to poor accrual.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0005
- source section id
- NCT00550654-om-0005
- source outcome index
- 5
- endpoint
- Pain at Sites of Metastases
- endpoint definition
- Improvement in pain from baseline will be assessed by the Brief Inventory for Pain criteria.
- time origin
- One and three months of follow up
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- No data/specimens were collected. Study was terminated due to poor accrual.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Radiation Therapy in Metastatic Cancer
- regimen
- Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00550654-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Radiation Therapy in Metastatic Cancer
- regimen
- Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
- analyzed count
- 1
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00550654-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0002
- arm key
- OG000
- arm label
- Radiation Therapy in Metastatic Cancer
- regimen
- Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00550654-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0003
- arm key
- OG000
- arm label
- Radiation Therapy in Metastatic Cancer
- regimen
- Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00550654-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0004
- arm key
- OG000
- arm label
- Radiation Therapy in Metastatic Cancer
- regimen
- Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00550654-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- outcome key
- om-0005
- arm key
- OG000
- arm label
- Radiation Therapy in Metastatic Cancer
- regimen
- Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
- analyzed count
- 0
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00550654-om-0005#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-ovarian-neoplasm
- nct id
- NCT00550654
- harm key
- EG000
- source section id
- NCT00550654-ae
- event group key
- EG000
- event group label
- Radiation Therapy in Metastatic Cancer
- serious affected
- 0
- serious at risk
- 1
- other affected
- 1
- other at risk
- 1
- frequency threshold
- 0
- collection period
- Source null
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice